A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease

Transplantation

Volumn 79, Issue 3, 2005, Pages 372-374

  Hori, Akiko ^a   Kanda, Yoshinobu ^b   Goyama, Susumu ^b   Onishi, Yasushi ^a   Komeno, Yukiko ^b   Mitani, Kinuko ^c   Kishi, Yukiko ^a   Ogawa, Seishi ^b   Imataki, Osamu ^a   Chiba, Shigeru ^b   Kojima, Rie ^a   Hamaki, Tamae ^a   Sakiyama, Michiyo ^a   Kami, Masahiro ^a   Makimoto, Atsushi ^a   Tanosaki, Ryuji ^a   Takaue, Yoichi ^a   Hirai, Hisamaru ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic graft versus host disease; Pravastatin; Treatment

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PRAVASTATIN; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPHENOTYPING; LIVER DISEASE; MALE; MOUTH DISEASE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN DISEASE; TH1 CELL; TH2 CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WEIGHT REDUCTION;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRAVASTATIN; TH1 CELLS; TH2 CELLS;

EID: 20044383914     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000151001.64189.1D     Document Type: Article

References (13)

1. Ratanatharathorn V, Ayash L, Lazarus HM, et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001; 28: 121.
2. Gaziev D, Galimberti M, Lucarelli G, et al. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant 2000; 25: 689.
3. Farag SS. Chronic graft-versus-host disease: where do we go from here? Bone Marrow Transplant 2004; 33: 569.
4. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
5. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation 1996; 61: 1469.
6. Arita S, Kasraie A, Une S, et al. Pravastatin and low-dose cyclosporine treatment prevent islet allograft rejection in mice. Transplant Proc 1998; 30: 522.
7. Kwak B, Mulhaupt F, Myit S, et al. Stalins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399.
8. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Stalins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687.
9. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219.
10. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553.
11. Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529.
12. Kanda H, Hamasaki K, Kubo K, et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 2002; 29: 2024.
13. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promoles a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78.